CClinicalTrials.gg
RecruitingNCT06512506Updated Jul 22, 2024

Prospective Cohort Study of Arthroscopic Treatment of Hip Dysplasia

An observational study in Developmental Dysplasia of the Hip, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-07-22.

Sponsored by Peking University Third Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
47
Sex
All
01

Study summary

On the basis of the database established in the previous stage, a cohort analysis was conducted on patients with BDDH complicated by hip arthroscopy for minimally invasive treatment of glenoid and lip injury, according to which the indications of minimally invasive surgery for BDDH patients were optimized and surgical measures were improved. Achieve accurate and rapid repair, rehabilitation and functional recovery, serve national fitness, and treat people's injuries

Read the detailed description

Based on the work of the previous research group, we prospective constructed a bidirectional cohort of patients with critical hip dysplasia, and summarized the influencing factors for the surgical prognosis of patients with BDDH, so as to continuously optimize patient selection. On this basis, the cohort size was extended to analyze the difference in efficacy between arthroscopic glenolabial repair and glenolabial repair combined with soft tissue enhancement, and further improve the minimally invasive surgery to promote the efficacy of minimally invasive surgery in BDDH patients

02

Conditions studied

03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Diagnosis of borderline hip dysplasia with glenolabial injury. (For example, there are no clinical symptoms of simple critical hip dysplasia, and hip pain may occur when combined with glenolabial injury

Inclusion criteria

  • Diagnosis of borderline hip dysplasia with glenolabial injury.

Exclusion criteria

Exclusion Criteria:

-

04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
47 participants (estimated)
Patient registry
No

Interventions

  • Othernon-intervention

    non-intervention

05

What researchers measure

Primary outcomes

  1. Improved Harris hip score

    It is suitable for the evaluation of therapeutic effect of various hip diseases. The Harris score includes pain, function, deformity and range of motion. The lower the improved Harris score, the worse the postoperative effect.

    Time frame: Preoperative, 24 months after surgery

  2. PRO rating

    Based on Patient-Reported Outcome (PRO) : Questionnaires were completed through face-to-face or telephone interviews. Patients' symptoms, function (activity restriction), pain score, quality of life and time to return to activity were evaluated comprehensively. The lower the PRO score, the worse the postoperative effect.

    Time frame: Preoperative, 24 months after surgery

  3. Cartilage damage outerbridge grading

    The patient underwent hip joint MR Examination at 12 months post-operative follow-up with T2 weighted intrachondral defect and high signal

    Time frame: Preoperative, 24 months after surgery

06

Study locations

1 of 1 sites recruiting
  • Peking University Third Hospital Medicial Science Research Ethics Committee
    Beijing, China
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06512506
Lead sponsor
Peking University Third Hospital
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Jan 1, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jul 22, 2024

Study contacts

Jianquan Wang, M.D.
Contact
wjqsportsmed@163.com
13253137009
Jianquan J Wang, M.D.
study chair · Peking University Third Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion